TIN2 Antibody (OTI2C12)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-44828
Key Product Details
Species Reactivity
Human, Mouse, Rat
Applications
Immunohistochemistry, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # OTI2C12
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Human recombinant protein fragment corresponding to amino acids 266-347 of human TINF2 (NP_036593) produced in E.coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Description
Novus Biologicals Mouse TIN2 Antibody (OTI2C12) (NBP3-44828) is a monoclonal antibody validated for use in IHC and WB. All Novus Biologicals antibodies are covered by our 100% guarantee.
Applications for TIN2 Antibody (OTI2C12)
Application
Recommended Usage
Immunohistochemistry
1:2000
Western Blot
1:500-2000
Formulation, Preparation, and Storage
Purification
>95%
Reconstitution
For reconstitution, we recommend adding 100uL distilled water to a final antibody concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process.
Formulation
Lyophilized powder ( 1X PBS, pH 7.3,)
Preservative
8% Trehalose
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20 degrees C. Avoid freeze/thaw cycles.
Background: TIN2
Alternate Names
(TRF1)-interacting nuclear factor 2 variant 1, TERF1 (TRF1)-interacting nuclear factor 2, TERF1-interacting nuclear factor 2, TIN2TRF1-interacting nuclear protein 2
Gene Symbol
TINF2
Additional TIN2 Products
Product Specific Notices for TIN2 Antibody (OTI2C12)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...